跳至主要内容
临床试验/IRCT201701162709N39
IRCT201701162709N39已完成未知

The effect of supplementation with sumac powder on liver enzymes (Alanine aminotransferase and Aspartate aminotransferase ), lipid profiles(Triglyceride,Total cholestrol,High density lipoprotein,Low density lipoprotein)? leptin and liver steatosis in patients with non-alcoholic fatty liver disease: a randomized controlled clinical trial

Vice Chancellor for Research of Iran university Medical Sciences0 个研究点目标入组 80 人开始时间: 待定最近更新:
适应症

试验速览

阶段
未知
状态
已完成
发起方
入组人数
80

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
20 years 至 60 years(—)
性别
All

入选标准

  • The criteria for inclusion: Age 20-60 years of both sexes, fatty liver disease be approved by physician gastroenterologist based on the following criteria: (ultrasound, volume Alastvmtry in fiberscan and> 4 kPa (kpa) or are in the process of steatosis S1 and Alanine transferase more than 5.1 times the upper limit of normal (women and men), Body Mass Index (BMI)25-29/9), a interested in participating the plan and received written informed consent, lack of participation in other projects.
  • Exclusion criteria:The patient's unwillingness to continue cooperation with the
  • Started taking the drug during the intervening period, Change the type or dose, Change in diet or physical activity program, Weight loss more than 10% of initial body weight during the intervention , Any use of antioxidant supplements, vitamins or minerals , Less than 80% supplements delivered to the patient at baseline, Start smoking during the intervening period, Become pregnant during treatment, Surgery and psychosomatic problems during the intervention, The use of all anti-NASH (vitamin E, thiazolidinedione, UDCA gemfibrozil,), Developing other liver diseases, kidney, kidney stones, cancer, hypothyroidism or hyperthyroidism, allergies, trauma during the intervention

排除标准

  • 未提供

研究者

发起方
Vice Chancellor for Research of Iran university Medical Sciences

相似试验